☆ 4.7 Article

Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome

JOURNAL OF NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Immunology

Clinical efficacy and safety of efgartigimod for treatment of myasthenia gravis

Ajith Sivadasan et al.

Summary: Therapies for myasthenia gravis (MG) aim to remove or suppress autoantibodies that cause the disease. The neonatal Fc receptor (FcRn) plays a role in recycling IgG antibodies, including IgG autoantibodies that are involved in MG. Blocking the FcRn receptor with a drug called efgartigimod can break down the autoantibodies and improve disease severity. Clinical trials have shown positive results with efgartigimod, making it a potential treatment strategy for MG. Studies are ongoing to further understand the effectiveness of efgartigimod. Summary Rating: 8/10

IMMUNOTHERAPY (2023)

Add to Collection

Review Hematology

Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications

Muharrem Yunce et al.

Summary: FcRn blockade, similar to plasma exchange (PLEX), can reduce immunoglobulin levels and has broad implications in apheresis. Multiple trials are underway with different FcRn therapies for neurological and hematological disorders mediated by IgG antibodies, as outlined in this review. This review discusses the mechanism of action of FcRn and its potential use in various diseases, comparing the kinetics and adverse events of PLEX and FcRn blockade. Apheresis practitioners are encouraged to familiarize themselves with this class of drugs to understand how FcRn antagonism and PLEX can be used to improve clinical outcomes by reducing IgG levels and pathogenic antibodies.

JOURNAL OF CLINICAL APHERESIS (2023)

Add to Collection

Article Clinical Neurology

Therapies in Stiff-Person Syndrome

Marinos C. Dalakas

Neurology-Neuroimmunology & Neuroinflammation (2023)

Add to Collection

Review Clinical Neurology

Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies

Marinos C. Dalakas

Summary: This article introduces several related syndromes of GAD antibody-spectrum disorders, which have similar autoimmune neuronal excitability symptoms. It also discusses the importance of high GAD antibody titers in diagnosis, as well as the association between high GAD antibodies and reduced GABA levels in the brain and CSF. In addition, it discusses current treatment methods and future immunotherapeutic options.

NEUROTHERAPEUTICS (2022)

Add to Collection

Article Clinical Neurology

Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome

Jessica Yi et al.

Summary: This study demonstrates that monthly maintenance IVIg therapy offers long-term benefits in 67% of patients with SPS for a median 3.3-year period. However, 29.1% of patients experienced diminishing benefit over time due to disease progression, highlighting the need for more effective therapies.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2022)

Add to Collection

Article Hematology

Plasma exchange in a bottle: An overview of efgartigimod for apheresis practitioners

Minh-Ha Tran

Summary: Efgartigimod is a first-in-class immunomodulatory agent comparable to TPE in reducing immunoglobulin levels. It effectively reduces Myasthenia Gravis symptom scores, with maximum effect observed after the fourth weekly dose. Efgartigimod received FDA approval in December 2021 and may serve as an alternative for patients receiving long-term TPE regimens. However, more studies are needed to establish its role in acute settings.

JOURNAL OF CLINICAL APHERESIS (2022)

Add to Collection

Article Medicine, General & Internal

Comparative Analysis of BIOCHIP Mosaic-Based Indirect Immunofluorescence with Enzyme-Linked Immunosorbent Assay for Diagnosing Myasthenia Gravis

Caterina Maria Gambino et al.

Summary: The study compared the BIOCHIP mosaic with conventional ELISA in the diagnosis of MG in 71 patients, showing a concordance of 74% for anti-AChR reactivity and 84% for anti-MuSK reactivity. However, overall concordance among assays is not optimal.

DIAGNOSTICS (2021)

Add to Collection

Article Clinical Neurology

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Jr Jr Howard et al.

Summary: The study evaluated the safety and efficacy of efgartigimod in patients with generalised myasthenia gravis, showing that it was well tolerated and efficacious. The unique feature of individualized dosing based on clinical response in the study will provide further insights into clinical practice with longer term data from the ongoing open-label extension.

LANCET NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions

Popianna Tsiortou et al.

Summary: GAD antibody-spectrum disorders (GAD-SD) encompass a wide range of clinical manifestations with overlapping features, highlighting autoimmune neuronal excitability disorders. Although antibody titers do not correlate with clinical severity, very high serum titers may indicate in-situ effects of GAD or related autoantibodies within the central nervous system.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Neurological Syndromes Associated with Anti-GAD Antibodies

Maelle Dade et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Editorial Material Clinical Neurology

Intranasal midazolam for treating acute respiratory crises in a woman with stiff person syndrome

Giuseppe Cosentino et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Subcutaneous immunoglobulin for maintenance therapy in stiff-person syndrome: One-year follow-up in two patients

E. Fileccia et al.

NEUROMUSCULAR DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Autologous hematopoietic stem cell transplantation for Stiff Person Spectrum Disorder: A clinical trial

Richard K Burt et al.

NEUROLOGY (2020)

Add to Collection

Review Immunology

Inflammatory polyradiculoneuropathies: Clinical and immunological aspects, current therapies, and future perspectives

Vincenzo Di Stefano et al.

EUROPEAN JOURNAL OF INFLAMMATION (2020)

Add to Collection

Letter Clinical Neurology

Severe breathlessness in Stiff person syndrome (SPS). Looking under the bonnet

Grazia Crescimanno et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Add to Collection

Article Clinical Neurology

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard et al.

NEUROLOGY (2019)

Add to Collection

Article Neurosciences

Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis

Maartje G. Huijbers et al.

EXPERIMENTAL NEUROLOGY (2019)

Add to Collection

Review Medicine, General & Internal

Anti-glutamate Dehydrogenase Antibody Positive Cerebellar Ataxia and Stiff Person Syndrome Responding to Dual Treatment wit h Steroids and Intravenous Immunoglobulin; A Case Presentation and Literature Review

Furkan M. Yilmaz et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2019)

Add to Collection

Article Medicine, General & Internal

Improving Ambulation and Minimizing Disability with Therapeutic Plasma Exchange in a Stiff-person Syndrome Patient with Recurrent Falls

Kyle Sanchez et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2019)

Add to Collection

Article Medicine, Research & Experimental

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts et al.

JOURNAL OF CLINICAL INVESTIGATION (2018)

Add to Collection

Editorial Material Pharmacology & Pharmacy

Kill 'Em All: Efgartigimod Immunotherapy for Autoimmune Diseases

Jagadeesh Bayry et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2018)

Add to Collection

Letter Neurosciences

Stiff-person syndrome after thymectomy in myasthenia gravis mimicking a post-thymectomy myasthenic crisis

Hye L. Lee et al.

NEUROLOGY INDIA (2017)

Add to Collection

Review Medicine, General & Internal

Myasthenia Gravis

Nils E. Gilhus

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Rheumatology

Stiff-Person Syndrome Persistent Elevation of Glutamic Acid Decarboxylase Antibodies Despite Successful Treatment With Rituximab

Eugene A. Bacorro et al.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.